Do BPC-157 or TB-500 heal tendons and soft tissue?
That has not been shown in reliable human trials. BPC-157 and TB-500 are sold with extraordinary confidence for recovery and repair. As of August 2026, the completed human evidence does not support that level of certainty.
- BPC-157
- A registered randomized hamstring study exists, but registration is not a result.
- TB-500
- FDA found no medical-literature study in which TB-500 was administered to humans.
- Both
- Neither is FDA-approved for pain, tendon healing, or wound repair.
Why the story sounds convincing
Animal and laboratory studies can show changes in blood vessels, inflammation, collagen organization, or tissue repair. Those findings are reasons to run human trials. They are not proof of meaningful recovery in an older adult with an Achilles tendon problem, rotator-cuff tear, or chronic muscle pain.
BPC-157: a trial has started, not finished
A registered study plans to compare BPC-157 with placebo in people with acute hamstring strains while both groups receive standardized rehabilitation. Its outcomes include return to sport, MRI injury volume, pain, strength, and function. Until results are posted and independently examined, the study cannot support a claim of benefit.
TB-500: less human evidence than the marketing implies
FDA’s July 2026 review found no human administration studies and no evidence establishing effectiveness for wound healing. FDA also distinguished TB-500 from full thymosin beta-4; websites often blur those names and borrow evidence from one for the other.
What should be identified first
Tendon pain can come from an acute tear, chronic tendinopathy, referred nerve pain, inflammatory disease, or a load problem that will remain after any injection. Imaging can be useful in selected cases, but an image finding also is not automatically the cause of pain. The useful question is what tissue is involved, why it is failing, and what outcome is being measured.
Our verdict: The possibility is worth studying. The confidence is not yet earned. Anyone selling guaranteed “regeneration” from BPC-157 or TB-500 is moving far beyond completed human evidence.
Primary sources
- FDA briefing document on BPC-157 (July 2026)
- Registered BPC-157 hamstring-injury study
- FDA briefing document on TB-500 (July 2026)
Last reviewed August 11, 2026. This page does not recommend an unapproved product.